Home
IMMX
IMMX News

Latest Immix Biopharma Inc. (IMMX) News on October 26, 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

IMMX

GlobeNewswire

12 days ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

IMMX

GlobeNewswire

20 days ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

IMMX

Zacks

5 months ago

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

Immix Biopharma Attends FDA CEO Forum in Washington DC

IMMX

GlobeNewswire

5 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

IMMX

Insider Monkey

5 months ago

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

IMMX

MT Newswires

5 months ago

Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

5 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

IMMX

GlobeNewswire

5 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

5 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

5 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

IMMX

Simply Wall St.

5 months ago

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

IMMX

GlobeNewswire

6 months ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

IMMX

MT Newswires

9 months ago

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

9 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Several Insiders Invested In Immix Biopharma Flagging Positive News

IMMX

Simply Wall St.

9 months ago

Several Insiders Invested In Immix Biopharma Flagging Positive News

IMMX

MT Newswires

10 months ago

Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX

GlobeNewswire

10 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX

MT Newswires

10 months ago

Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

IMMX

GlobeNewswire

10 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

10 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

IMMX

MT Newswires

a year ago

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

IMMX

GlobeNewswire

a year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

IMMX

Simply Wall St.

a year ago

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

IMMX

GlobeNewswire

a year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$